NextCell Pharma AB (OSTO:NXTCL) EPS (Basic) : kr-0.91 (TTM As of May. 2024)

View and export this data going back to 2017. Start your Free Trial

What is NextCell Pharma AB EPS (Basic)?

NextCell Pharma AB's basic earnings per share (Basic EPS) for the three months ended in May. 2024 was kr-0.26. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in May. 2024 was kr-0.91.

NextCell Pharma AB's EPS (Diluted) for the three months ended in May. 2024 was kr-0.26. Its EPS (Diluted) for the trailing twelve months (TTM) ended in May. 2024 was kr-0.91.

NextCell Pharma AB's EPS without NRI for the three months ended in May. 2024 was kr-0.26. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in May. 2024 was -0.91.

During the past 3 years, the average EPS without NRI Growth Rate was -19.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 0.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 9 years, NextCell Pharma AB's highest 3-Year average EPS without NRI Growth Rate was 19.70% per year. The lowest was -19.60% per year. And the median was -1.50% per year.

NextCell Pharma AB EPS (Basic) Historical Data

The historical data trend for NextCell Pharma AB's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCell Pharma AB EPS (Basic) Chart

NextCell Pharma AB Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

EPS (Basic)

Get a 7-Day Free Trial

-0.63

-0.54

-0.56

-0.82

-0.92

NextCell Pharma AB Quarterly Data
	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24
EPS (Basic)	Get a 7-Day Free Trial															-0.32	-0.20	-0.22	-0.23	-0.26

NextCell Pharma AB EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

NextCell Pharma AB's Basic EPS for the fiscal year that ended in Aug. 2023 is calculated as

Basic EPS (A: Aug. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-39.812	-	0)	/	43.525
	=	-0.91

NextCell Pharma AB's Basic EPS for the quarter that ended in May. 2024 is calculated as

Basic EPS (Q: May. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-8.822	-	0)	/	34.380
	=	-0.26

EPS (Basic) for the trailing twelve months (TTM) ended in May. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.91

NextCell Pharma AB (OSTO:NXTCL) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

NextCell Pharma AB EPS (Basic) Related Terms

Thank you for viewing the detailed overview of NextCell Pharma AB's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

NextCell Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCell Pharma AB (OSTO:NXTCL) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

65G:Germany

Address

Karolinska Institutet Science Park, Halsovagen 7, Huddinge, SWE, 14157

Website

http://www.nextcellpharma.com

NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.

NextCell Pharma AB Headlines

No Headlines